Free Trial
→ Altucher: Turn $900 into $108,000 in just 12 months? (From Paradigm Press) (Ad) Buy ARDT Stock  Free ARDT Stock Alerts

Ardent Health Partners (ARDT) Financials

Ardent Health Partners logo
$13.18 +0.59 (+4.69%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$13.18 0.00 (0.00%)
As of 05/2/2025 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Ardent Health Partners

Annual Income Statements for Ardent Health Partners

This table shows Ardent Health Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 31 54 210
Consolidated Net Income / (Loss)		 265 129 300
Net Income / (Loss) Continuing Operations		 108 129 300
Total Pre-Tax Income 		311 152 363
Total Operating Income		 154 150 337
Total Gross Profit		 1,539 3,025 3,431
Total Revenue		 5,130 5,409 5,966
Operating Revenue		 5,130 5,409 5,966
Total Cost of Revenue		 3,591 2,384 2,535
Operating Cost of Revenue		 3,591 2,384 2,535
Total Operating Expenses		 1,385 2,875 3,095
Selling, General & Admin Expense		 1,201 2,425 2,626
Depreciation Expense		 138 141 146
Other Operating Expenses / (Income)		 47 309 322
Total Other Income / (Expense), net		 0.00 1.61 26
Other Income / (Expense), net		 - 1.61 26
Income Tax Expense		 46 23 63
Net Income / (Loss) Attributable to Noncontrolling Interest		 76 75 89
Basic Earnings per Share		 $1.50 $0.43 $1.59
Weighted Average Basic Shares Outstanding		 126.12M 126.12M 132.44M
Diluted Earnings per Share		 $1.50 $0.43 $1.58
Weighted Average Diluted Shares Outstanding		 126.12M 126.12M 132.74M
Weighted Average Basic & Diluted Shares Outstanding		 - - 142.75M

Quarterly Income Statements for Ardent Health Partners

This table shows Ardent Health Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q2 2024 Q3 2024
Period end date 6/30/2023 9/30/2023 6/30/2024 9/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 33 21 43 26
Consolidated Net Income / (Loss)		 56 39 67 46
Net Income / (Loss) Continuing Operations		 56 39 67 46
Total Pre-Tax Income 		68 46 82 57
Total Operating Income		 67 46 84 54
Total Gross Profit		 770 782 847 815
Total Revenue		 1,369 1,378 1,471 1,450
Operating Revenue		 1,369 1,378 1,471 1,450
Total Cost of Revenue		 598 596 624 635
Operating Cost of Revenue		 598 596 624 635
Total Operating Expenses		 703 736 763 760
Selling, General & Admin Expense		 596 621 647 644
Depreciation Expense		 35 35 36 37
Other Operating Expenses / (Income)		 72 80 80 80
Total Other Income / (Expense), net		 0.52 0.00 -1.64 2.81
Other Income / (Expense), net		 0.52 0.00 0.26 2.81
Income Tax Expense		 12 7.26 15 11
Net Income / (Loss) Attributable to Noncontrolling Interest		 23 18 24 20
Basic Earnings per Share		 $0.26 $0.17 $0.34 $0.19
Weighted Average Basic Shares Outstanding		 126.12M 126.12M 126.12M 137.11M
Diluted Earnings per Share		 $0.26 $0.17 $0.34 $0.19
Weighted Average Diluted Shares Outstanding		 126.12M 126.12M 126.12M 137.54M
Weighted Average Basic & Diluted Shares Outstanding		 - - 142.76M 142.73M

Annual Cash Flow Statements for Ardent Health Partners

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -262 -19 119
Net Cash From Operating Activities		 -38 222 315
Net Cash From Continuing Operating Activities		 -38 222 315
Net Income / (Loss) Continuing Operations		 265 129 300
Consolidated Net Income / (Loss)		 265 129 300
Depreciation Expense		 138 141 146
Amortization Expense		 5.70 4.99 5.47
Non-Cash Adjustments To Reconcile Net Income		 -323 -0.75 26
Changes in Operating Assets and Liabilities, net		 -125 -52 -162
Net Cash From Investing Activities		 47 -138 -220
Net Cash From Continuing Investing Activities		 47 -138 -220
Purchase of Property, Plant & Equipment		 -151 -137 -188
Acquisitions		 0.00 0.00 -36
Divestitures		 206 0.00 4.30
Other Investing Activities, net		 -8.69 -0.58 -1.71
Net Cash From Financing Activities		 -270 -102 25
Net Cash From Continuing Financing Activities		 -270 -102 25
Repayment of Debt		 -28 -146 -106
Repurchase of Common Equity		 -1.95 -26 -9.53
Payment of Dividends		 -244 -64 -73
Issuance of Debt		 0.88 132 3.60
Issuance of Common Equity		 0.00 0.00 209
Other Financing Activities, net		 2.50 1.87 0.35
Cash Interest Paid		 91 82 75
Cash Income Taxes Paid		 56 19 42

Quarterly Cash Flow Statements for Ardent Health Partners

This table details how cash moves in and out of Ardent Health Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q3 2024 Q4 2024
Period end date 9/30/2023 12/31/2023 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 40 -7.10 229 -6.36
Net Cash From Operating Activities		 89 67 90 120
Net Cash From Continuing Operating Activities		 89 67 90 120
Net Income / (Loss) Continuing Operations		 39 11 46 141
Consolidated Net Income / (Loss)		 39 11 46 141
Depreciation Expense		 35 36 37 38
Amortization Expense		 1.42 0.72 1.38 1.23
Non-Cash Adjustments To Reconcile Net Income		 0.39 -5.09 8.42 13
Changes in Operating Assets and Liabilities, net		 13 25 -2.86 -73
Net Cash From Investing Activities		 -25 -57 -45 -105
Net Cash From Continuing Investing Activities		 -25 -57 -45 -105
Purchase of Property, Plant & Equipment		 -25 -57 -43 -81
Acquisitions		 - - -0.24 -27
Other Investing Activities, net		 0.24 0.74 -0.80 -0.97
Net Cash From Financing Activities		 -24 -18 183 -20
Net Cash From Continuing Financing Activities		 -24 -18 183 -20
Repayment of Debt		 -4.06 -128 -1.50 3.21
Repurchase of Common Equity		 - - -5.81 -0.90
Payment of Dividends		 -19 -13 -21 -20
Other Financing Activities, net		 -0.98 -6.99 1.74 -3.07

Annual Balance Sheets for Ardent Health Partners

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024
Period end date 12/31/2023 12/31/2024
Total Assets		 4,732 4,956
Total Current Assets		 1,618 1,833
Cash & Equivalents		 438 557
Accounts Receivable		 775 743
Inventories, net		 105 115
Prepaid Expenses		 77 114
Other Current Assets		 222 304
Plant, Property, & Equipment, net		 811 862
Total Noncurrent Assets		 2,302 2,261
Goodwill		 845 852
Intangible Assets		 77 77
Noncurrent Deferred & Refundable Income Taxes		 32 12
Other Noncurrent Operating Assets		 1,348 1,320
Total Liabilities & Shareholders' Equity		 4,732 4,956
Total Liabilities		 3,649 3,434
Total Current Liabilities		 994 945
Short-Term Debt		 19 9.23
Accounts Payable		 475 401
Accrued Expenses		 501 535
Total Noncurrent Liabilities		 2,655 2,488
Long-Term Debt		 1,168 1,086
Other Noncurrent Operating Liabilities		 1,487 1,403
Commitments & Contingencies		 0.00 0.00
Redeemable Noncontrolling Interest		 7.30 1.16
Total Equity & Noncontrolling Interests		 1,075 1,521
Total Preferred & Common Equity		 671 1,131
Preferred Stock		 0.00 0.00
Total Common Equity		 671 1,131
Common Stock		 497 756
Retained Earnings		 155 366
Accumulated Other Comprehensive Income / (Loss)		 19 9.74
Noncontrolling Interest		 404 390

Quarterly Balance Sheets for Ardent Health Partners

This table presents Ardent Health Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024
Period end date 6/30/2024 9/30/2024
Total Assets		 4,609 4,800
Total Current Assets		 1,501 1,691
Cash & Equivalents		 335 563
Accounts Receivable		 721 706
Inventories, net		 105 108
Prepaid Expenses		 136 120
Other Current Assets		 205 194
Plant, Property, & Equipment, net		 807 815
Total Noncurrent Assets		 2,300 2,294
Goodwill		 852 852
Intangible Assets		 77 77
Noncurrent Deferred & Refundable Income Taxes		 35 35
Other Noncurrent Operating Assets		 1,336 1,331
Total Liabilities & Shareholders' Equity		 4,609 4,800
Total Liabilities		 3,446 3,413
Total Current Liabilities		 909 887
Short-Term Debt		 11 12
Accounts Payable		 371 369
Accrued Expenses		 527 506
Total Noncurrent Liabilities		 2,537 2,526
Long-Term Debt		 1,082 1,084
Other Noncurrent Operating Liabilities		 1,456 1,442
Commitments & Contingencies		 0.00 0.00
Redeemable Noncontrolling Interest		 3.67 2.39
Total Equity & Noncontrolling Interests		 1,159 1,384
Total Preferred & Common Equity		 740 1,006
Preferred Stock		 - 0.00
Total Common Equity		 740 1,006
Common Stock		 498 745
Retained Earnings		 225 252
Accumulated Other Comprehensive Income / (Loss)		 17 9.49
Noncontrolling Interest		 419 379

Annual Metrics and Ratios for Ardent Health Partners

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 5.45% 10.29%
EBITDA Growth		 0.00% -0.03% 73.08%
EBIT Growth		 0.00% -1.34% 139.46%
NOPAT Growth		 0.00% -2.53% 117.88%
Net Income Growth		 0.00% -51.40% 132.37%
EPS Growth		 0.00% -71.33% 267.44%
Operating Cash Flow Growth		 0.00% 677.96% 42.10%
Free Cash Flow Firm Growth		 0.00% 0.00% 102.88%
Invested Capital Growth		 0.00% 0.00% 12.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 30.00% 55.93% 57.51%
EBITDA Margin		 5.80% 5.50% 8.63%
Operating Margin		 3.00% 2.77% 5.65%
EBIT Margin		 3.00% 2.80% 6.09%
Profit (Net Income) Margin		 5.17% 2.38% 5.02%
Tax Burden Percent		 85.20% 85.07% 82.55%
Interest Burden Percent		 202.69% 100.00% 100.00%
Effective Tax Rate		 14.80% 14.93% 17.45%
Return on Invested Capital (ROIC)		 0.00% 13.93% 14.29%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 14.30% 17.65%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 9.90% 8.73%
Return on Equity (ROE)		 0.00% 23.83% 23.01%
Cash Return on Invested Capital (CROIC)		 0.00% -186.07% 2.52%
Operating Return on Assets (OROA)		 0.00% 3.20% 7.50%
Return on Assets (ROA)		 0.00% 2.73% 6.19%
Return on Common Equity (ROCE)		 0.00% 14.77% 15.92%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 19.22% 26.49%
Net Operating Profit after Tax (NOPAT)		 131 128 278
NOPAT Margin		 2.55% 2.36% 4.66%
Net Nonoperating Expense Percent (NNEP)		 0.00% -0.37% -3.37%
Return On Investment Capital (ROIC_SIMPLE)		 - 5.64% 10.63%
Cost of Revenue to Revenue		 70.00% 44.07% 42.49%
SG&A Expenses to Revenue		 23.41% 44.84% 44.02%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 27.01% 53.16% 51.87%
Earnings before Interest and Taxes (EBIT)		 154 152 363
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 298 297 515
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.29 2.15
Price to Tangible Book Value (P/TBV)		 0.00 0.00 12.05
Price to Revenue (P/Rev)		 0.04 0.04 0.41
Price to Earnings (P/E)		 6.17 3.56 11.59
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 16.20% 28.08% 8.63%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.74 1.63
Enterprise Value to Revenue (EV/Rev)		 0.00 0.25 0.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 4.55 6.54
Enterprise Value to EBIT (EV/EBIT)		 0.00 8.92 9.27
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 10.60 12.11
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 6.10 10.69
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 68.72
Leverage & Solvency		 - - -
Debt to Equity		 0.00 1.10 0.72
Long-Term Debt to Equity		 0.00 1.08 0.71
Financial Leverage		 0.00 0.69 0.49
Leverage Ratio		 0.00 4.37 3.72
Compound Leverage Factor		 0.00 4.37 3.72
Debt to Total Capital		 0.00% 52.30% 41.84%
Short-Term Debt to Total Capital		 0.00% 0.82% 0.35%
Long-Term Debt to Total Capital		 0.00% 51.48% 41.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 18.13% 14.94%
Common Equity to Total Capital		 0.00% 29.57% 43.23%
Debt to EBITDA		 0.00 3.99 2.13
Net Debt to EBITDA		 0.00 2.52 1.05
Long-Term Debt to EBITDA		 0.00 3.93 2.11
Debt to NOPAT		 0.00 9.30 3.94
Net Debt to NOPAT		 0.00 5.87 1.94
Long-Term Debt to NOPAT		 0.00 9.16 3.91
Altman Z-Score		 0.00 1.48 2.19
Noncontrolling Interest Sharing Ratio		 0.00% 38.01% 30.81%
Liquidity Ratios		 - - -
Current Ratio		 0.00 1.63 1.94
Quick Ratio		 0.00 1.22 1.37
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -1,704 49
Operating Cash Flow to CapEx		 -25.39% 161.34% 168.01%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 1.14 1.23
Accounts Receivable Turnover		 0.00 6.98 7.86
Inventory Turnover		 0.00 22.60 22.98
Fixed Asset Turnover		 0.00 6.67 7.13
Accounts Payable Turnover		 0.00 5.02 5.79
Days Sales Outstanding (DSO)		 0.00 52.32 46.45
Days Inventory Outstanding (DIO)		 0.00 16.15 15.88
Days Payable Outstanding (DPO)		 0.00 72.65 63.06
Cash Conversion Cycle (CCC)		 0.00 -4.18 -0.72
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 1,832 2,061
Invested Capital Turnover		 0.00 5.91 3.07
Increase / (Decrease) in Invested Capital		 0.00 1,832 229
Enterprise Value (EV)		 0.00 1,353 3,367
Market Capitalization		 192 192 2,438
Book Value per Share		 $0.00 $5.32 $7.93
Tangible Book Value per Share		 $0.00 ($1.99) $1.42
Total Capital		 0.00 2,269 2,617
Total Debt		 0.00 1,187 1,095
Total Long-Term Debt		 0.00 1,168 1,086
Net Debt		 0.00 749 538
Capital Expenditures (CapEx)		 151 137 188
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 205 340
Debt-free Net Working Capital (DFNWC)		 0.00 643 897
Net Working Capital (NWC)		 0.00 624 887
Net Nonoperating Expense (NNE)		 -134 -1.37 -22
Net Nonoperating Obligations (NNO)		 0.00 749 538
Total Depreciation and Amortization (D&A)		 144 146 152
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 3.79% 5.70%
Debt-free Net Working Capital to Revenue		 0.00% 11.88% 15.03%
Net Working Capital to Revenue		 0.00% 11.53% 14.87%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.59
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 132.44M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.58
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 132.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 142.75M
Normalized Net Operating Profit after Tax (NOPAT)		 131 128 278
Normalized NOPAT Margin		 2.55% 2.36% 4.66%
Pre Tax Income Margin		 6.07% 2.80% 6.09%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 92.02% 49.52% 24.31%
Augmented Payout Ratio		 92.75% 69.70% 27.49%

Quarterly Metrics and Ratios for Ardent Health Partners

This table displays calculated financial ratios and metrics derived from Ardent Health Partners' official financial filings.

Metric Q2 2023 Q3 2023 Q2 2024 Q3 2024
Period end date 6/30/2023 9/30/2023 6/30/2024 9/30/2024
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 7.47% 5.23%
EBITDA Growth		 0.00% 0.00% 17.47% 14.88%
EBIT Growth		 0.00% 0.00% 23.98% 24.14%
NOPAT Growth		 0.00% 0.00% 23.55% 13.01%
Net Income Growth		 0.00% 0.00% 20.20% 18.85%
EPS Growth		 0.00% 0.00% 30.77% 11.76%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 1.19%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.66% 0.00% -1.43%
EBITDA Q/Q Growth		 0.00% -19.13% 0.00% -20.91%
EBIT Q/Q Growth		 0.00% -32.22% 0.00% -32.13%
NOPAT Q/Q Growth		 0.00% -29.98% 0.00% -35.96%
Net Income Q/Q Growth		 0.00% -30.51% 0.00% -31.30%
EPS Q/Q Growth		 0.00% -34.62% 0.00% -44.12%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1.26%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -0.06%
Profitability Metrics		 - - - -
Gross Margin		 56.29% 56.77% 57.57% 56.19%
EBITDA Margin		 7.49% 6.02% 8.18% 6.57%
Operating Margin		 4.92% 3.34% 5.70% 3.74%
EBIT Margin		 4.95% 3.34% 5.72% 3.94%
Profit (Net Income) Margin		 4.07% 2.81% 4.55% 3.17%
Tax Burden Percent		 82.14% 84.20% 81.48% 80.62%
Interest Burden Percent		 100.00% 100.00% 97.74% 100.00%
Effective Tax Rate		 17.86% 15.80% 18.52% 19.38%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 55 39 68 44
NOPAT Margin		 4.04% 2.81% 4.64% 3.02%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.35% -0.85%
Cost of Revenue to Revenue		 43.71% 43.23% 42.43% 43.81%
SG&A Expenses to Revenue		 43.57% 45.05% 43.96% 44.40%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 51.37% 53.43% 51.87% 52.44%
Earnings before Interest and Taxes (EBIT)		 68 46 84 57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 102 83 120 95
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.26 2.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 34.10
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.71 1.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.94 0.79
Long-Term Debt to Equity		 0.00 0.00 0.93 0.78
Financial Leverage		 0.00 0.00 0.65 0.38
Leverage Ratio		 0.00 0.00 3.96 3.46
Compound Leverage Factor		 0.00 0.00 3.87 3.46
Debt to Total Capital		 0.00% 0.00% 48.45% 44.14%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.48% 0.49%
Long-Term Debt to Total Capital		 0.00% 0.00% 47.97% 43.65%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 18.74% 15.35%
Common Equity to Total Capital		 0.00% 0.00% 32.81% 40.51%
Debt to EBITDA		 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 0.00 1.65 1.91
Quick Ratio		 0.00 0.00 1.16 1.43
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -1,853 -1,876
Operating Cash Flow to CapEx		 0.00% 354.48% 0.00% 206.37%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -976.03 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 0.00 1,921 1,920
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 1,921 1,920
Enterprise Value (EV)		 0.00 0.00 1,373 3,538
Market Capitalization		 192 192 192 2,624
Book Value per Share		 $0.00 $0.00 $5.87 $7.05
Tangible Book Value per Share		 $0.00 $0.00 ($1.50) $0.54
Total Capital		 0.00 0.00 2,255 2,483
Total Debt		 0.00 0.00 1,093 1,096
Total Long-Term Debt		 0.00 0.00 1,082 1,084
Net Debt		 0.00 0.00 758 533
Capital Expenditures (CapEx)		 0.00 25 0.00 43
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 269 252
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 603 816
Net Working Capital (NWC)		 0.00 0.00 593 803
Net Nonoperating Expense (NNE)		 -0.43 0.00 1.34 -2.26
Net Nonoperating Obligations (NNO)		 0.00 0.00 758 533
Total Depreciation and Amortization (D&A)		 35 37 36 38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.34 $0.19
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 126.12M 137.11M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.34 $0.19
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 126.12M 137.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 142.76M 142.73M
Normalized Net Operating Profit after Tax (NOPAT)		 55 39 68 44
Normalized NOPAT Margin		 4.04% 2.81% 4.64% 3.02%
Pre Tax Income Margin		 4.95% 3.34% 5.59% 3.94%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 44.30 0.00
NOPAT to Interest Expense		 0.00 0.00 35.99 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Ardent Health Partners' Financials

When does Ardent Health Partners's financial year end?

According to the most recent income statement we have on file, Ardent Health Partners' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ardent Health Partners' net income changed over the last 2 years?

Ardent Health Partners' net income appears to be on an upward trend, with a most recent value of $299.71 million in 2024, rising from $265.37 million in 2022. The previous period was $128.98 million in 2023. See where experts think Ardent Health Partners is headed by visiting Ardent Health Partners' forecast page.

What is Ardent Health Partners's operating income?
Ardent Health Partners's total operating income in 2024 was $336.80 million, based on the following breakdown:
  • Total Gross Profit: $3.43 billion
  • Total Operating Expenses: $3.09 billion
How has Ardent Health Partners revenue changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' total revenue changed from $5.13 billion in 2022 to $5.97 billion in 2024, a change of 16.3%.

How much debt does Ardent Health Partners have?

Ardent Health Partners' total liabilities were at $3.43 billion at the end of 2024, a 5.9% decrease from 2023, and a 5.9% decrease since 2023.

How much cash does Ardent Health Partners have?

In the past 1 years, Ardent Health Partners' cash and equivalents has ranged from $437.58 million in 2023 to $556.79 million in 2024, and is currently $556.79 million as of their latest financial filing in 2024.

How has Ardent Health Partners' book value per share changed over the last 2 years?

Over the last 2 years, Ardent Health Partners' book value per share changed from 0.00 in 2022 to 7.93 in 2024, a change of 792.7%.


Related Companies

This page (NYSE:ARDT) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Why Elon put $51 million into this
While fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...
True Market Insiders | Sponsored
Will May start the next "Great Depression?"
You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...
Behind the Markets | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
All Signs Point To Collapse - 401(k)s/IRAs /Are Doomed
Retiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road Ahead
American Hartford Gold | Sponsored